Crossmark

CAR T-Cell Therapy in the Older Person: Indications and Risks

Published Online: 2022-04-14

Published Print: 2022-09

Authors

Shouse, Geoffrey https://orcid.org/0000-0002-7917-5713
Danilov, Alexey V.

Artz, Andy
License Information

Text and Data Mining valid from 2022-04-14

Version of Record valid from 2022-04-14
More Information

Article History

Accepted: 25 February 2022

First Online: 14 April 2022

Declarations

:

: Geoffrey Shouse reports receiving speaker honoraria from Kite Pharmaceuticals and honoraria from Beigene. Alexey V. Danilov reports the following conflicts of interest: consulting fees from AstraZeneca, Abbvie, BeiGene, Gamida Cell, Genentech, Lilly Oncology, Morphosys, TG Therapeutics, Bayer Oncology, and Pharmacyclics and has ongoing research funding from AstraZeneca, Takeda Oncology, Bayer Oncology, SecuraBio, MEI, TG Therapeutics, and Bristol Myers Squibb. Andy Artz reports no direct conflicts but reports an equity interest in Radiology Partners and has received consulting fees from Abbvie.

Document is current